Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2004

View Archived Issues

Prous Science announces publication of a comprehensive review on sleep apnea

Takeda presents metastin derivatives for cancer therapy and other uses

New monoamine reuptake inhibitors developed at NeuroSearch

Novel chemokine CCR3 modulators and their use described by Boehringer Ingelheim

Two series of PTP inhibitors presented by TransTech researchers

Novel ALK4/ALK5 inhibitors discovered at Biogen Idec

New androgen receptor antagonists in early development at Pfizer

New Nurr1 activators with potential utility in PD therapy

New p38 MAP kinase inhibitors and their use claimed by Pfizer

Novo Nordisk updates program progress

Canadian approval for Lipitor to lower risk of heart attack

E.U. regulators to review long-term cardiovascular safety data for COX-2 inhibitors

Clinical investigators meeting endorses phase II ThromboView study

Transition Therapeutics sells Stem Cell Therapeutics to Neurogenesis Biotech

Takeda signs agreement to market Tavocept in U.S. and Canada

European approval sought for Surfaxin

Phase II study set to open this month evaluating Zyflo for acne

Small-molecule GSK-3 inhibitor stimulates bone formation in vitro and in vivo

Synthetic peptide promotes fracture healing in mouse model

Combination therapy overcomes resistance of prostate cancer cells to apoptosis

Epothilone derivative promising in human gliomas and drug-resistant melanomas

PI3K antagonist enhances radiation-induced vascular destruction in tumors

Good safety profile of anidulafungin in patients with invasive candidiasis

Clinical trials confirm the antifungal efficacy and safety of posaconazole

Liposomal-encapsulated paclitaxel well tolerated in prostate cancer patients

Development of mycobacterial cell wall-DNA complex advances

Beta-blocking drugs reduce risk of fractures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.